Breaking News Instant updates and real-time market news.

RDUS

Radius Health

$27.41

0.71 (2.66%)

18:34
12/07/17
12/07
18:34
12/07/17
18:34

Radius Healths says elacestrant still 'shows promise' in advanced breast cancer

Radius Health provided an update on data from the Phase 1 005 clinical study of elacestrant, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. The data were presented at a Spotlight Presentation during the 2017 San Antonio Breast Cancer Symposium. Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. There are 40 patients that have been treated at the 400 mg dose in the elacestrant Phase I dose escalation and expansion cohorts. All study participants are heavily pretreated ER+, HER2-negative, advanced breast cancer patients that have received a median of three prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were 6 confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea, dyspepsia and vomiting. "It is quite encouraging to see the clinical activity with elacestrant in the heavily pretreated advanced patient population, and further therapeutic development is warranted for patients with hormone receptor positive breast cancer", commented Dr. Aditya Bardia, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

RDUS Radius Health
$27.41

0.71 (2.66%)

05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.

TODAY'S FREE FLY STORIES

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

, LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

05:20
12/15/17
12/15
05:20
12/15/17
05:20
Recommendations
Campbell Soup, Snyder's-Lance analyst commentary  »

Campbell deal for…

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$83.87

0.84 (1.01%)

05:16
12/15/17
12/15
05:16
12/15/17
05:16
Recommendations
Tesaro analyst commentary  »

Tesaro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:13
12/15/17
12/15
05:13
12/15/17
05:13
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRC

First Republic

$88.54

-0.27 (-0.30%)

05:11
12/15/17
12/15
05:11
12/15/17
05:11
Downgrade
First Republic rating change  »

First Republic downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$83.87

0.84 (1.01%)

05:10
12/15/17
12/15
05:10
12/15/17
05:10
Hot Stocks
Tesaro announces availability of Zejula in Germany »

Tesaro announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCM

Hutchison China MediTech

$31.11

0.05 (0.16%)

05:09
12/15/17
12/15
05:09
12/15/17
05:09
Hot Stocks
Hutchison China MediTech initiates fruquintinib U.S. clinical trials »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

, CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

05:09
12/15/17
12/15
05:09
12/15/17
05:09
Recommendations
Snyder's-Lance, Campbell Soup analyst commentary  »

Snyder's-Lance worth…

LNCE

Snyder's-Lance

$44.42

5.01 (12.71%)

CPB

Campbell Soup

$48.56

-0.63 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$57.31

-0.38 (-0.66%)

05:07
12/15/17
12/15
05:07
12/15/17
05:07
Hot Stocks
CSX announces medical leave of CEO, COO James Foote named acting CEO »

CSX announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:03
12/15/17
12/15
05:03
12/15/17
05:03
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

05:00
12/15/17
12/15
05:00
12/15/17
05:00
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$53.13

-0.6 (-1.12%)

04:59
12/15/17
12/15
04:59
12/15/17
04:59
Upgrade
Sonoco Products rating change  »

Sonoco Products upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$48.03

-0.22 (-0.46%)

, AVY

Avery Dennison

$114.28

-0.09 (-0.08%)

04:58
12/15/17
12/15
04:58
12/15/17
04:58
Upgrade
Sealed Air, Avery Dennison rating change  »

Sealed Air upgraded to…

SEE

Sealed Air

$48.03

-0.22 (-0.46%)

AVY

Avery Dennison

$114.28

-0.09 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.80

-0.1 (-0.92%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$52.49

-0.35 (-0.66%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
MetLife to hold a conference call »

Investor outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

  • 12

    Jun

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

November Industrial…

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Breaking General news story  »

Week of 12/15…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Cable, Media &…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

DIS

Disney

$110.57

2.96 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

04:55
12/15/17
12/15
04:55
12/15/17
04:55
General news
Industrial Production to be reported at 09:15 »

November Industrial…

ADRNY

Ahold Delhaize

$21.69

-0.14 (-0.64%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Ahold Delhaize management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

BASFY

BASF

$27.57

-0.17 (-0.61%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
BASF management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CUTR

Cutera

$47.20

-1.3 (-2.68%)

, TESO

Tesco

$3.70

-0.25 (-6.33%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Hot Stocks
Cutera to replace Tesco in S&P 600 at open on 12/15 »

MidCap 400 constituent…

CUTR

Cutera

$47.20

-1.3 (-2.68%)

TESO

Tesco

$3.70

-0.25 (-6.33%)

NBR

Nabors Industries

$5.58

-0.23 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

RCKZF

Rocket Internet

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Rocket Internet management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

PJT

PJT Partners

$44.10

-0.24 (-0.54%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
PJT Partners management to meet with Sandler O'Neill »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

JAGX

Jaguar Health

$0.13

0.0068 (5.52%)

04:55
12/15/17
12/15
04:55
12/15/17
04:55
Conference/Events
Jaguar Health to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.